Neurocrine Biosciences (NBIX) : Blue Jay Capital Management reduced its stake in Neurocrine Biosciences by 14.27% during the most recent quarter end. The investment management company now holds a total of 305,630 shares of Neurocrine Biosciences which is valued at $14,786,379 after selling 50,880 shares in Neurocrine Biosciences , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Neurocrine Biosciences makes up approximately 8.76% of Blue Jay Capital Management’s portfolio.
Other Hedge Funds, Including , Group One Trading sold out all of its stake in NBIX during the most recent quarter. The investment firm sold 17,559 shares of NBIX which is valued $849,504.Blackrock Advisors reduced its stake in NBIX by selling 57,627 shares or 5.66% in the most recent quarter. The Hedge Fund company now holds 960,256 shares of NBIX which is valued at $46,457,185. Neurocrine Biosciences makes up approx 0.05% of Blackrock Advisors’s portfolio.Mutual Of America Capital Management boosted its stake in NBIX in the latest quarter, The investment management firm added 200 additional shares and now holds a total of 71,904 shares of Neurocrine Biosciences which is valued at $3,619,647. Neurocrine Biosciences makes up approx 0.07% of Mutual Of America Capital Management’s portfolio.Palisade Capital Managementnj reduced its stake in NBIX by selling 56,524 shares or 38.94% in the most recent quarter. The Hedge Fund company now holds 88,638 shares of NBIX which is valued at $4,462,037. Neurocrine Biosciences makes up approx 0.19% of Palisade Capital Managementnj’s portfolio.Moody Aldrich Partners boosted its stake in NBIX in the latest quarter, The investment management firm added 21,125 additional shares and now holds a total of 30,960 shares of Neurocrine Biosciences which is valued at $1,573,387. Neurocrine Biosciences makes up approx 1.25% of Moody Aldrich Partners’s portfolio.
Neurocrine Biosciences closed down -0.23 points or -0.46% at $49.31 with 4,38,000 shares getting traded on Monday. Post opening the session at $49.67, the shares hit an intraday low of $48.96 and an intraday high of $49.8 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Neurocrine Biosciences reported $-0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.49.During the same quarter in the previous year, the company posted $-0.28 EPS.
Many Wall Street Analysts have commented on Neurocrine Biosciences. H.C. Wainwright Initiated Neurocrine Biosciences on Jun 29, 2016 to “Buy”, Price Target of the shares are set at $80.
Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.